Omeros (OMER) Q3 2024 earnings summary

Executive summary

• Net loss for Q3 2024 was $32.2 million ($0.56/share), improving from $56 million ($0.97/share) in Q2 2024 and $37.8 million ($0.60/share) in Q3 2023, mainly due to lower R&D expenses and reduced narsoplimab manufacturing costs.

• Cash and investments totaled $123.2 million as of September 30, 2024, down $35.8 million from June 30, 2024, and $48.7 million from year-end 2023.

• OMIDRIA royalty sale to DRI Healthcare includes two contingent milestone payments of up to $27.5 million each, with all U.S. royalties through 2031 assigned to DRI.

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring losses, negative cash flows, and significant debt.

• Key pipeline progress: FDA presubmission meeting for narsoplimab BLA in TA-TMA, with resubmission expected pending efficacy analyses; zaltenibart advancing to Phase 3 in PNH and C3G, with rare pediatric disease designation for C3G.

Financial highlights

• Q3 2024 net loss was $32.2 million; nine-month net loss was $125.5 million.

• Q3 OMIDRIA royalties were $9.3 million on $31 million net sales, down from $10.9 million on $36.4 million in Q2 and $10.0 million on $33.3 million in Q3 2023.

• Q3 operating expenses were $35.4 million, down from $48.2 million in Q3 2023.

• Interest expense for Q3 was $4.1 million, down from $7.9 million in Q3 2023, aided by debt retirements and OMIDRIA royalty obligation changes.

• Net income from discontinued operations (OMIDRIA) was $4.9 million for Q3 2024.

Outlook and guidance

• Operating costs for Q4 expected to be similar to Q3; interest income projected at $1.2 million and interest expense at $7.2 million.

• Income from discontinued operations anticipated at $7–8 million for Q4.

• Narsoplimab BLA resubmission for TA-TMA pending FDA feedback and efficacy analyses; European MAA submission expected in H1 2025.

• Zaltenibart Phase 3 enrollment in PNH targeted for early 2025; C3G Phase 3 to follow.

• OMS527 clinical study in cocaine use disorder may begin in 2025, pending preclinical results.